Eli Lilly Expands Olumiant Reach With FDA Approval for Adolescent Alopecia
FDA approval for adolescent alopecia broadens Olumiant’s reach and reinforces Eli Lilly’s immunology strategy beyond GLP-1 drugs.
Iovance Shares Rally as Survey Points to Strong Amtagvi Demand in Melanoma
A proprietary analyst survey is lifting sentiment around IOVA, but its demand signal is not the same…
Abeona Shares Draw Buy Rating After FDA Approval of FAYUVI Gene Therapy
H.C. Wainwright reiterated a Buy rating on Abeona after FDA approval of partner Ultragenyx’s FAYUVI …
Eli Lilly Shares Rise 3.7% After FDA Clears Once-Weekly Onswik Insulin
FDA approval of once-weekly Onswik lifted LLY shares 3.73%, adding another pillar to Eli Lilly’s dia…
GoDaddy Stock Jumps 6% as Reported Gen Digital Takeover Interest Sparks Fresh M&A Focus
GoDaddy shares jumped about 6% after a report of takeover interest from Gen Digital, putting deal co…
MGM Resorts Stock Drops 9% After People Inc. Withdraws Takeover Offer
MGM Resorts shares fell 9% after People Inc. withdrew its offer, removing takeover-premium expectati…
Eli Lilly Stock Nears $1,200 After Weekly Insulin Approval and $3.25 Billion InnoCare Deal
Eli Lilly shares reached $1,191.92 after FDA approval of weekly insulin Onswik and a $3.25 billion I…
Elmet Group's Strategic Move: Acquiring Stake in Tungsten Supply Amid Rising Demand
Elmet Group's $125 million acquisition signals a pivotal shift in the tungsten supply landscape for …
aTyr Pharma's FDA Protocol Alignment Sparks Pre-Market Surge: What Investors Need to Know
aTyr Pharma's stock jumped 9.8% in pre-market trading after FDA trial protocol alignment, highlighti…
Eli Lilly's Onswik Approval: A Game Changer for Diabetes Management and Investment Potential
Eli Lilly's recent FDA approval of Onswik represents a significant advancement in diabetes treatment…